- Home
- TIXT vs VIR Comparison
TIXT vs VIR Comparison
Compare TIXT & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIXT
- VIR
- Stock Information
- Founded
- TIXT 2005
- VIR 2016
- Country
- TIXT Canada
- VIR United States
- Employees
- TIXT N/A
- VIR N/A
- Industry
- TIXT EDP Services
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- TIXT Technology
- VIR Health Care
- Exchange
- TIXT Nasdaq
- VIR Nasdaq
- Market Cap
- TIXT 812.7M
- VIR 844.9M
- IPO Year
- TIXT 2021
- VIR 2019
- Fundamental
- Price
- TIXT $3.62
- VIR $5.13
- Analyst Decision
- TIXT Hold
- VIR Strong Buy
- Analyst Count
- TIXT 9
- VIR 7
- Target Price
- TIXT $4.17
- VIR $32.86
- AVG Volume (30 Days)
- TIXT 1.4M
- VIR 1.1M
- Earning Date
- TIXT 08-01-2025
- VIR 07-31-2025
- Dividend Yield
- TIXT N/A
- VIR N/A
- EPS Growth
- TIXT N/A
- VIR N/A
- EPS
- TIXT N/A
- VIR N/A
- Revenue
- TIXT $2,671,000,000.00
- VIR $20,861,000.00
- Revenue This Year
- TIXT $3.61
- VIR N/A
- Revenue Next Year
- TIXT $3.59
- VIR N/A
- P/E Ratio
- TIXT N/A
- VIR N/A
- Revenue Growth
- TIXT N/A
- VIR N/A
- 52 Week Low
- TIXT $2.13
- VIR $4.32
- 52 Week High
- TIXT $6.86
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- TIXT 67.03
- VIR 48.62
- Support Level
- TIXT $3.61
- VIR $5.00
- Resistance Level
- TIXT $3.76
- VIR $5.35
- Average True Range (ATR)
- TIXT 0.14
- VIR 0.24
- MACD
- TIXT 0.03
- VIR 0.02
- Stochastic Oscillator
- TIXT 85.22
- VIR 31.21
About TIXT TELUS International (Cda) Inc. Subordinate Voting Shares
TELUS International (Cda) Inc is a digital customer experience innovator that designs, builds, and delivers next-generation solutions. Its clients include companies across several verticals, including Tech and Games, eCommerce and FinTech, Banking, Financial Services and Insurance, Communications and Media, and Healthcare. The solutions offered by the company include Digital Experience, Customer Experience, Advisory Services, and Back Office and Automation among other services. Geographically, it derives a majority of its revenue from the European region.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.